Respiratory
Latest news
198 articles · 20 / page
Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis
A secondary analysis of 159 mechanically ventilated ARDS patients shows that increasing trunk inclination reduces respiratory system, lung, and chest wall compliance—especially in patients with obesity—and is associated with increased PaCO2
Inhaled PEG‑Adrenomedullin in ARDS: Safe but Ineffective — Phase 2 RCT Stopped for Futility
A multicentre randomized Phase 2a/b trial found inhaled pegylated adrenomedullin (PEG‑ADM) well tolerated in ventilated ARDS patients but without improvement in ventilator‑free survival or a composite clinical utility index; the study was s
Rescue Noninvasive Ventilation After Extubation: High Failure but No Clear Increase in Hospital Mortality — A Post‑hoc RINO Trial Analysis
A post‑hoc analysis of the RINO trial found rescue NIV for post‑extubation respiratory failure had a 58% failure rate but was associated with lower ICU mortality and no clear increase in hospital mortality when applied with prespecified re‑
Cardiovascular and Respiratory Responses During Graded Exercise in Adolescents After Sport-Related Concussion: A Synthesis of Current Evidence
Exploring altered cardiopulmonary dynamics and exercise intolerance in adolescents post-sport-related concussion reveals attenuated cardiovascular responses independent of aerobic deconditioning, highlighting autonomic dysregulation as a ke
Brensocatib Shows Imaging Signals of Structural Benefit in Non‑CF Bronchiectasis: CT Substudy from ASPEN Suggests Reduced Mucus Plugging and Modest Airway Change
A 100‑patient CT substudy from the ASPEN program found that brensocatib, especially the 25‑mg dose, reduced mucus plugging and increased healthy parenchyma at 52 weeks, providing preliminary imaging evidence that it may modify disease biolo
ICS–Formoterol Users Show Lower Reported Adherence but Less SABA Use: Real‑World Evidence from the MASK‑air Asthma App
Analysis of MASK‑air app data from 2015–2022 found lower self‑reported adherence to ICS+formoterol versus other ICS+LABA combinations, but paradoxically lower short‑acting β2‑agonist (SABA) use and similar symptom control in ICS+formoterol
Adjunctive Low-Dose Glucocorticoids Reduce Mortality in Community-Acquired Pneumonia in Low-Resource Settings: Evidence from a Kenyan Pragmatic Trial
A pragmatic randomized trial in Kenyan public hospitals demonstrates that adjunctive low-dose glucocorticoid therapy significantly reduces 30-day mortality in adults with community-acquired pneumonia without increasing serious adverse event
Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study
A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.
Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial
This phase 2 trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, significantly reduces active type I collagen deposition in IPF lungs, indicating antifibrotic potential and favorable lung remodeling over 12 weeks.
Unveiling Diverse Inflammatory Pathways in Residual Pediatric Asthma Exacerbations Under Mepolizumab Therapy
This study reveals multiple distinct molecular mechanisms, including epithelial and macrophage pathways, that contribute to residual asthma exacerbations in children treated with mepolizumab, highlighting the complexity of airway inflammati
Evaluating the Cost-Effectiveness of Early In-Bed Cycling Plus Routine Physiotherapy in Mechanically Ventilated ICU Patients: Insights from the CYCLE Trial
This economic evaluation from the CYCLE randomized trial found no significant cost or quality-adjusted life-year benefit by adding early in-bed cycling to usual physiotherapy for ICU patients on mechanical ventilation, underscoring a need f
Evaluating Portable HEPA Purifiers to Reduce Respiratory Viral Exposure in Elementary Schools: Insights from a Randomized Clinical Trial Secondary Analysis
A secondary analysis of a cluster-randomized trial found that portable HEPA purifiers modestly reduced viral diversity but did not significantly lower high respiratory viral exposure in elementary school classrooms, suggesting multi-faceted
Impact of COVID-19 Restrictions on Immunity to Streptococcus pyogenes and Respiratory Viruses in Early Childhood
This study examines how pandemic-related nonpharmaceutical interventions affected immunity development to Streptococcus pyogenes and common respiratory viruses in children aged 0-4 years, offering insights into rising invasive infections.
Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis
This article reviews a phase 3 trial analyzing sotatercept’s efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.
Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope
This article reviews recent clinical trial data showing sevabertinib’s efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.
Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study
This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.
Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances
This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.
Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib
This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.
Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy
This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.
Bridging the Gap after Pulmonary Rehabilitation: Evaluating the PICk UP Programme in COPD Management
A randomized trial shows that a six-month personalised community-based physical activity programme sustains physical activity improvements and functional performance post-pulmonary rehabilitation in COPD patients, though other health benefi
Browse by specialty
Open language-specific specialty feeds and department pages.